Brennpunkt Urologie 2025

Innovating Bladder Cancer Profiling - Meet Us at Brennpunkt Urologie 2025!

As targeted therapies evolve, molecular profiling of Bladder Cancer comes to the forefront. There is a growing need for reliable solutions that would deliver comprehensive data without delay.

And BIOTYPE is bringing innovative solutions to the table! Our MODAPLEX platform and Bladder Cancer assay portfolio allow you to detect 25 FGFR gene alterations in less than 5 hours. Tested on 200 Bladder Cancer samples with 95% concordance to gold standard PCR assays - that is the precision you can trust!

‍Our Bladder Cancer portfolio includes:

• MODAPLEX FGFR3 Mutation Kit
• MODAPLEX FGFR Gene Fusion Kit
• And more assays are under development!

Schedule a meeting with Dr. Timm Zörgiebel to discuss the details and discover how BIOTYPE is shaping the future of molecular cancer research.